The biopharmaceutical company has licensed its VAL401 asset to Ambrose Healthcare for £16 million plus royalties, providing the firm with secured funding and a strategic partnership.
The biopharmaceutical company is hosting an investor webinar to discuss its latest developments.
The biopharmaceutical company has announced a change in its shareholding structure.
The biotech firm reported reduced losses and increased cash balance, but faces material uncertainty about its ability to continue as a going concern, highlighting the challenges in early-stage drug development.
The biopharmaceutical company has entered an agreement with a California-based corporation to evaluate the use of its oncolytic peptide technology in enhancing the activity of the partner's next-generation oncolytic virus immunotherapies.
The biopharmaceutical company ValiRx has announced a director has increased their stake in the company.
The life sciences company has extended an evaluation and commercial use agreement with Dominion Biotech to share data and commercialise any repurposed drugs.
The biopharmaceutical company has announced commercial deals for its Inaphaea BioLabs subsidiary, providing access to its cancer model biobank.
The biopharmaceutical company has terminated its letter of intent with TheoremRx, citing a decision by TheoremRx not to proceed with an amendment to the agreement.
The biopharmaceutical company announces changes to its board of directors and the formation of a new advisory board to provide scientific, commercial and strategic advice.